Search Results

Final Design Review Completed for ITER Neutron Flux Monitor System #7

Recently, the Final Design Review (FDR-2) for the ITER Neutron Flux Monitor System #7 (NFM#7), led by the Southwestern Institute of Physics (SWIP), was successfully held, and the system design scheme was fully affirmed by the review expert panel. The successful passage of this review marks an important milestone achievement in China's development of key ITER diagnostic systems, laying a solid foundation for subsequent system manufacturing and overall delivery. At the review meeting, the project team comprehensively reported the overall and component-level design schemes of the NFM#7 system, and responded item by item to the inquiries raised by ITER international review experts. The expert panel unanimously agreed that the final design of the NFM#7 system...

2026-10-09

China Becomes First to Achieve Operation of a Thorium-229 Nuclear Optical Clock, Bringing Quantum Precision Measurement into the Atomic Nucleus Scale

Recently, the team of Ding Shiqian, associate professor in the Department of Physics at Tsinghua University, published important results online in the international academic journal Nature, announcing the successful development of a thorium-229 nuclear optical clock and the achievement of its stable operation. This work was completed independently in the same period as that of a European team, making China the first internationally to achieve operation of a thorium-229 nuclear optical clock, marking the successful extension of the time measurement standard from electronic transitions to nuclear transitions. It is understood that a nuclear optical clock uses the internal transition of the thorium-229 atomic nucleus as a time-frequency reference. Ding Shiqian, one of the corresponding authors of the paper, introduced that the pendulum of an old-fashioned wall clock swings about once per second, whereas a nuclear optical clock uses the beat of the atomic nucleus as its "pendulum," with a beat frequency of up to about 2 quadrillion times per second. Because the size of the atomic nucleus is only a few tens of thousandths of the electron cloud outside the nucleus...

2026-10-08

Romania's National Nuclear Power Company Plans to Borrow EUR 800 Million from the European Investment Bank: Full Speed Ahead on the Refurbishment of Cernavodă NPP Unit 1

Romania's National Nuclear Power Company (Nuclearelectrica) recently submitted a disclosure to the Bucharest Stock Exchange (BVB), announcing plans to obtain a long-term loan totaling EUR 800 million from the European Investment Bank (BEI), earmarked to finance the Unit 1 Refurbishment and modernization project at the Cernavodă NPP. This major external financing plan has been placed on the agenda and will be formally submitted to shareholders for approval and deliberation at an extraordinary general meeting to be held from October 29 to 30, 2026. The European Investment Bank's Board of Directors had previously formally approved on July 15, 2026, an EUR 800 million credit facility for the project, which is...

2026-10-08

GE HealthCare Plans $945 Million All-Cash Acquisition of Sofie Biosciences: Full-Scale Positioning in the "Final Mile" Delivery of Positron Radiopharmaceuticals and CDMO Capacity

GE HealthCare, the Chicago-based medical imaging and radiodiagnostics giant, has announced that it has entered into a definitive acquisition agreement to acquire radiopharmaceutical company Sofie Biosciences in an all-cash deal valued at $945 million from private equity firm Trilantic North America. The transaction is expected to complete all regulatory approvals and closing procedures by July 2027, and is expected to be accretive to GE HealthCare's revenue growth and adjusted earnings in the first full fiscal year following closing. Founded in 2008 and headquartered in Dulles, Virginia, Sofie Biosciences has built a broad radiopharmaceutical production and distribution network across the United States...

2026-10-08

The neutral beam injection system prototype independently developed by Shuyan Juchuang has been officially completed and completed its first plasma discharge.

Recently, the neutral beam injection (NBI) system prototype independently developed by Shuyan Juchuang, a domestic upstream commercialization company in controlled nuclear fusion, was officially completed, and on September 30, 2026, it successfully completed the first neutral beam plasma discharge verification. This marks the landing of China's first neutral beam engineering verification prototype fully independently developed along the entire chain by an upstream fusion commercialization company, achieving a technical closed loop from system design to productization verification. It is expected that the relevant capabilities of the system will reach an engineering state ready for direct commercial procurement in December this year. With the smooth completion and successful discharge of this prototype, the company's 2026 annual strategic goals set at the beginning of the year have all...

2026-10-08

Russian Scholars Analyze the Technical Secrets Behind the 2026 Nobel Prize in Physics: How IceCube Uses Photomultiplier Tubes to Capture Neutrino Tracks

The 2026 Nobel Prize in Physics was awarded for a major scientific discovery in the field of astrophysical high-energy neutrino detection. The key engineering foundation that made this historic breakthrough possible is a giant scientific facility located near the South Pole——the IceCube Neutrino Observatory. The facility uses nearly 1 cubic kilometer of highly transparent deep Antarctic ice as a natural detection medium, and densely arrays thousands of digital optical modules deep within the ice. Genrikh Scheibler, senior researcher and Candidate of Physical and Mathematical Sciences at the Institute of Semiconductor Physics of the Siberian Branch of the Russian Academy of Sciences (ISP SB RAS), has...

2026-10-08

Europe Completes Delivery of Final ITER Vacuum Vessel Sector, Marking Conclusion of 16 Years of Manufacturing

Recently, Fusion for Energy (F4E), in collaboration with Ansaldo Nucleare, Westinghouse, and Walter Tosto, has completed the manufacturing of Europe's final vacuum vessel sector for the International Thermonuclear Experimental Reactor (ITER) and delivered it to the ITER project site at Cadarache in southeastern France. It is understood that the ITER vacuum vessel has an internal volume of 1,400 cubic meters and is composed of nine wedge-shaped steel sectors, each over 14 meters tall and weighing up to 440 tonnes. Once assembled, the vacuum vessel will have an outer diameter of 19.4 meters, a height of 11.4 meters, and weigh approximately 520...

2026-10-06

Hanul Unit 6 in South Korea commences its 15th planned preventive overhaul

Korea Hydro & Nuclear Power (KHNP)'s Hanul Nuclear Power Site announced that its Hanul Unit 6 was officially disconnected from the grid at 10:00 a.m. on September 30, fully launching its 15th planned preventive overhaul lasting approximately 72 days. Hanul Unit 6 is a 1,000-megawatt-class pressurized water reactor (PWR) with a rated electrical power of 1,000 megawatts. During this planned maintenance window, the operations and maintenance team will carry out routine nuclear fuel assembly refueling operations as scheduled, and conduct comprehensive preventive maintenance and performance testing on the reactor primary coolant system, engineered safety features, and conventional island critical...

2026-10-04

General Matter Submits HALEU License Application to U.S. NRC

Paducah, Kentucky, USA — General Matter submitted a license application to the U.S. Nuclear Regulatory Commission (NRC) on September 28, 2026, for the construction and operation of a nuclear facility. The project aims to produce High-Assay Low-Enriched Uranium (HALEU) to meet the growing domestic demand for advanced nuclear reactor fuel in the United States. General Matter plans to build a dedicated HALEU production...

2026-09-29

Dongfang Electric Signs Low-Pressure Diaphragm Supply Agreement with Électricité de France, Supporting the Upgrade and Retrofit of European Pressurized Water Reactor Nuclear Power Units

Recently, Dongfang Electric International Corporation (hereinafter referred to as "Dongfang International"), a subsidiary of China Dongfang Electric Group Co., Ltd., and Arabelle, a subsidiary of Électricité de France (EDF), officially signed a nuclear power steam turbine low-pressure diaphragm supply agreement. According to the agreement, Dongfang Electric will serve as a key equipment supplier, providing core steam turbine low-pressure diaphragm components for the life extension and modernization technical retrofit projects of pressurized water reactor (PWR) nuclear power units under Électricité de France. For more than three decades, Dongfang Electric Group and Électricité de France have consistently maintained close strategic collaboration in the field of civil nuclear energy, from...

2026-09-28

FDA Approves Lantheus' Bravnetsa for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors

The U.S. Food and Drug Administration (FDA) has formally approved Lantheus Holdings' radioligand therapy drug Bravnetsa (lutetium Lu 177 dotatate injection) for the treatment of somatostatin receptor-positive adult gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The approved indication covers neuroendocrine tumors originating from the foregut, midgut, and hindgut. Following FDA review, Bravnetsa has been determined to be bioequivalent and therapeutically equivalent to Novartis'...

2026-09-27

Samsung C&T Teams Up with GE, Hitachi and Synthos to Enter Europe's Small Modular Reactor Market

Samsung C&T's construction division has partnered with GE Vernova, Hitachi and Synthos Green Energy (SGE) to expand into Europe's small modular reactor (SMR) market. By integrating technology, engineering, procurement and construction (EPC) and business development capabilities, the parties aim to establish a business model for the repeat deployment of standardized small modular reactors across European countries. Samsung C&T announced on the 23rd that it signed a memorandum of understanding (MOU) on the 22nd (local time) with GE Vernova, Hitachi and SGE to pursue market development and commercial...

2026-09-23

Centrus Energy to Supply HALEU Fuel to Antares Nuclear, Enabling Micro Nuclear Reactor Applications for Military and Space

U.S. nuclear fuel supplier Centrus Energy has signed a multi-year contract with advanced microreactor developer Antares Nuclear, under which Centrus will supply high-assay low-enriched uranium (HALEU) to Antares. This agreement is expected to expand the application scenarios of micro nuclear reactors to locations where traditional power sources are difficult to use, such as military facilities and space environments. As part of the agreement, Antares Nuclear will make advance payments to support Centrus in expanding HALEU production capacity in the United States. Compared with conventional low-enriched uranium, HALEU contains more uranium-235, with an enrichment level above 5% but below 20%. This new type of fuel can support smaller, higher-energy-density reac...

2026-09-18

Microstructure Imaging's MICSI-PET Software Receives FDA Clearance to Enhance Neurological PET Imaging Using MRI

Microstructure Imaging's software platform has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The platform is designed to enhance neurological positron emission tomography (PET) images using structural magnetic resonance imaging (MRI). The software, called MICSI-PET, can denoise and super-resolve PET images using MRI guidance while preserving quantitative PET information. It supports PET exams for amyloid, Tau, and FDG (fluorodeoxyglucose), and can provide automated Centiloid measurements for amyloid imaging and CenTauR measurements for Tau imaging....

2026-09-18

Curium's Lutetium-177 Injection Approved by FDA for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Radiopharmaceutical company Curium recently announced that its developed lutetium-177 (Lu-177) dotatate injection (trade name: Bexlutry) has received formal approval from the U.S. Food and Drug Administration (FDA). The drug is indicated for the treatment of somatostatin receptor-positive adult gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The specific indication scope includes various neuroendocrine tumors occurring in the adult foregut, midgut, and hindgut. Bexlutry is an advanced radioligand therapy whose mechanism of action lies in its ability to specifically bind to somatostatin receptors highly expressed on the surface of such tumors. Through this precise binding, the drug can deliver...

2026-09-16